Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first-line therapy in patients with extensive-stage small cell lung cancer

The majority of previous studies of lobaplatin in small cell lung cancer (SCLC) are small phase I–II studies. The present study aimed to verify the non-inferiority (in terms of efficacy) of lobaplatin plus etoposide (EL) vs. cisplatin plus etoposide (EP) in patients with previously untreated extensi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncol Lett
Päätekijät: Cheng, Ying, Fan, Yun, Liu, Xiaoqing, Liu, Yunpeng, Liu, Jiwei, Wang, Dong, Yu, Yan, Qin, Shukui, Liu, Wei, Huang, Cheng, Zhang, Helong, Liang, Jun, Shi, Jianhua, Sheng, Lijun, Yu, Hao
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: D.A. Spandidos 2019
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6447897/
https://ncbi.nlm.nih.gov/pubmed/30988825
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2019.10125
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia